Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
384.244663718
InChI
InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
InChI Key
InChIKey=ALOBUEHUHMBRLE-UHFFFAOYSA-N
IUPAC Name
N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
Traditional IUPAC Name
ibutilide
SMILES
CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
pKa (strongest acidic)
9.72
pKa (Strongest Basic)
10.4
Refractivity
109.18 m3·mol-1
Dược Lực Học :
Ibutilide prolongs the action potential duration and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act.
Cơ Chế Tác Dụng :
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. [Wikipedia]
Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels
Dược Động Học :
▧ Absorption :
Rapid after intravenous injection
▧ Volume of Distribution :
* 11 L/kg
▧ Protein binding :
40%
▧ Metabolism :
Primarily hepatic. Eight metabolites of ibutilide were detected in metabolic profiling of urine. These metabolites are thought to be formed primarily by o-oxidation followed by sequential b-oxidation of the heptyl side chain of ibutilide. Of the eight metabolites, only the o-hydroxy metabolite possesses class III electrophysiologic properties similar to that of ibutilide in an in vitro isolated rabbit myocardium model.
▧ Route of Elimination :
In healthy male volunteers, about 82% of a 0.01 mg/kg dose of [14C] ibutilide fumarate was excreted in the urine (about 7% of the dose as unchanged ibutilide) and the remainder (about 19%) was recovered in the feces.
▧ Half Life :
6 hours (ranges from 2-12 hours)
▧ Clearance :
* 29 mL/min/kg
Độc Tính :
Acute overdose in animals results in CNS toxicity; notably, CNS depression, rapid gasping breathing, and convulsions. The intravenous median lethal dose in the rat was more than 50 mg/kg which is, on a mg/m2 basis, at least 250 times the maximum recommended human dose.
Chỉ Định :
Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Tương Tác Thuốc :
-
Artemether
Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
-
Cisapride
Increased risk of cardiotoxicity and arrhythmias
-
Fingolimod
Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
-
Lumefantrine
Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
-
Ranolazine
Possible additive effect on QT prolongation
-
Tacrolimus
Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
-
Telavancin
Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
-
Thiothixene
May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
-
Toremifene
Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
-
Trimipramine
Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
-
Voriconazole
Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
-
Vorinostat
Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
-
Ziprasidone
Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
-
Zuclopenthixol
Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng :
Solution - Intravenous
Tài Liệu Tham Khảo Thêm
National Drug Code Directory